290 Krascendo 2: A phase III study of divarasib and pembrolizumab vs pembrolizumab and chemotherapy in patients with previously untreated, advanced or metastatic, KRAS G12C-mutated non-small cell lung cancer (NSCLC)

Lung Cancer 2026

View at publisher
Authors: Ferdinandos Skoulidis, Benjamin Solomon, N. Frost, Rebecca Suk Heist, Caicun Zhou, Martina Zarak Crnkovic, Vladan Antic, Hen Prizant, Mariah Mayo, Christoph Meyenberg, Sophie Keufer-Le Gall, Sanjay Popat
DOI: 10.1016/j.lungcan.2026.109238
Cited by: 1

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Melanoma and MAPK Pathways Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
Lung Cancer
Publisher
Elsevier BV
Volume
212
Pages
109238–109238
Publication date
1 February 2026
Language
EN